Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03895203
Recruitment Status : Active, not recruiting
First Posted : March 29, 2019
Last Update Posted : May 20, 2022
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma SRL )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 17, 2021
Estimated Study Completion Date : July 2022